Now approved:
Imfinzi® + Lynparza® regimen in pMMR advanced and recurrent endometrial cancer

The first PARPI + IO combination that extends mPFS (15 vs 9.7 months) and more than doubles median duration of response (18.7 vs 7.6 months) vs CP alonein pMMR EC 1-4,*

Setting eligible endometrial cancer patients on a new course with the IMFINZI®+ LYNPARZA® regimen

Endometrial cancer and the need for new treatment options

In pMMR, PARP inhibition may complement the effects of IO+CP

The Imfinzi® + Lynparza® Regimen is the first approved PARP +IO combination that extends mPFS vs CP alone in in pMMR EC (p-value not tested)

*As determined by an FDA-approved companion diagnostic for LYNPARZA®

FDA, Food and Drug Administration; gBRCA, germline BRCA; gBRCAm, germline BRCA mutation; mPaC, metastatic pancreatic cancer; PARP, poly (ADP-ribose) polymerase.

References: 1. LYNPARZA®. Summary of Product Characteristics. 2. Rubraca® (rucaparib). Summary of Product Characteristics; 3. Talzenna® (talazoparib). Summary of Product Characteristics; 4. Zejula® (niraparib). Summary of Product Characteristics; 5. Akeega® (niraparib and abiraterone acetate). Prescribing information. 6. LYNPARZA® (olaparib). Prescribing information.

MMR proficient (pMMR) endometrial cancer is complex and heterogeneous with high unmet needs5–7

pMMR endometrial cancer is associated with a poor prognosis, accounting for 70-80% of all advanced or recurrent cases5

pMMR endometrial cancer is associated with a poor prognosis, accounting for 70-80% of all advanced or recurrent cases5

pMMR endometrial cancer is associated with a poor prognosis, accounting for 70-80% of all advanced or recurrent cases5

pMMR endometrial cancer is associated with a poor prognosis, accounting for 70-80% of all advanced or recurrent cases5

 

 

Patients with advanced/recurrent pMMR EC need more effective and durable treatment options 7,12

PARP inhibition may complement the effects of IO + CP by promoting a more robust antitumour immunity and more durable benefit14–16

pMMR tumors are heterogeneous, with diverse genomic drivers. Compared to dMMR EC tumours, they have a lower tumour mutational burden, scarce immune infiltration and therefore limited ability to mount an antitumour response.17–19

IO + CP drives direct tumour cell killing.However, blockade of PD-L1 provides limited immune response because of the reduced mutational burden and neoantigen load of pMMR tumours.5,17,18,20–22

PARP inhibition induces DNA damage and cell death which may enhance immune priming and stimulate immune responses. This can potentiate robust antitumour immune response and may support a durable benefit to PARPi + IO combination treatment.14–16

Immunosuppressive
tumour microenvironment
Immunostimulatory
tumour microenvironment

The The Imfinzi® + Lynparza® Regimen is the first approved IO+PARP regimen that extends mPFS vs CP alone in pMMR EC (p- value not tested)1-4

Analysis of PFS by MMR status was a prespecified exploratory analyses, respectively3
The DUO-E/GOG-3041/ENGOT-EN10 trial demonstrated that the addition of the anti-PD-L1 antibody Imfinzi® to standard first-line chemotherapy, followed by Imfinzi® or Imfinzi® + Lynparza®, improves outcomes in newly diagnosed advanced or recurrent
endometrial cancer.3
The Imfinzi® + Lynparza® regimen was generally well tolerated, with the regimen safety profile consistent with known profiles of individual components.1-4
Find out more about the efficacy and safety profile of the Imfinzi® + CP with or without Lynparza regimens here

 

 

CP, Carboplatin and Paclitaxel; DNA, deoxyribonucleic acid; dMMR, mismatch repair deficient; EC, Endometrial cancer; IO, Immuno-oncology; PARP, poly-ADP ribose polymerase; PARPi, poly-ADP ribose polymerase inhibitor; PD-L1, programmed death-ligand 1; pMMR, Proficient Mismatch repair.

References: 1. LYNPARZA®. (olaparib). Summary of Product Characteristics. 2. IMFINZI. (durvalumab) Summary of Product Characteristics. 3. Westin SN et al. J Clin Oncol. 2023;42:283–299. 4. Chon HS, et al. SGO Annual Meeting on Women’s Cancer 16–18 March 2024. San Diego, USA. Oral presentation. 5. Corr B, et al. BMJ Med. 2022;1:e000152. 6. Mirza MR, et al. N Engl J Med. 2023;388:2145–2158 7. Kelkar SS, et al. Gynecol Oncol Rep. 2022;42:101026. 8. Cao S, et al. BMC Cancer. 2023;23:31. 9. Heffernan K, et al. Gyn Oncol. 2022;166:317–325.10. Murali R, et al. Int J Gynecol Pathol. 2019;38:S40–S63. 11. Jamieson A, et al. Ther Adv Med Oncol. 2021;13:1–14. 12. Dio CD, et al. Gynecol Oncol. 2023;169:27–33. 13. Fountzilas E, et al. ESMO Open. 2019;4:e000474. 14. Stewart RA, et al. Cancer Res. 2018;78:6717– 6725. 15. Musacchio L, et al. Cancer Manag Res. 2020;12:6123-6135. 16. Post CCB, et al. Crit Rev Oncol Hematol. 2020;152:102973. 17.Rizzo A, et al. J Clin Med. 2022;11:3912. 18. Yang Y, et al. Int J Gynaecol Obstet. 2024;164:436–459. 19. Antill Y, et al. Cancer. 2022;128 1157–1161. 20. Eskander RN & Powell MA. Ther Adv Med Oncol. 2021;13:1–9. 21. Liu T-Y, et al. Theranostics. 2021;11:5365–5386. 22. El-ghazzi N, et al. Onco Targets Ther. 2023;16:359–369.

Back to top